Abstract: Aspects of the disclosure are directed to a method for use on a blockchain network that includes an accounting node subnetwork having accounting nodes configured to record a data block onto a blockchain and a service node having service nodes configured to verify data blocks recorded by the accounting nodes onto the blockchain. The method can include generating a signature based on transaction information to be included in a data block to be added onto the blockchain by using a key specific to the accounting node. The method can further include adding the transaction information and the generated signature to the data block and adding the data block onto the blockchain, and transmitting the signature to the service nodes in the service node subnetwork, so that the service nodes perform signature verification on the signature based on the key specific to the accounting node.

Abstract: This application provide a data management method for a blockchain system, a medium, and an electronic device. The system includes an accounting node sub-network and a service node sub-network. The method includes: adding, after an accounting node generates a first data block, first key information used for verifying a block header of a second data block generated after the first data block to a block header of the first data block; generating a signature corresponding to the first data block, and adding the signature corresponding to the first data block to the block header of the first data block; and releasing the block header of the first data block to the service node sub-network, to cause a service node to verify the signature included in the block header of the first data block, and obtaining the first key information after a successful verification to verify the block header of the second data block.

Abstract: A chimeric antigen receptor, includes an extracellular domain, a transmembrane domain, and an intracellular domain, which are connected in sequence, where the extracellular domain includes an antigen recognition region and a hinge region, and one end of the intracellular domain which is connected to the transmembrane domain is connected to a CD3? intracellular region. The chimeric antigen receptor can further improve the treatment effect of B-cell leukemia lymphoma, and reduce inflammatory cytokines generated from macrophage mononuclear cell activation by down-regulating cytokines, so that cytokine storm can be prevented in an early stage, and the risk of neurotoxicity can be reduced. The treatment effect of mesothelin high-expression solid tumors is further improved in mesothelin-positive tumor treatment, and the prevention of cytokine storm and the reduced risk of neurotoxicity can be realized at an early stage.

Abstract: A chimeric antigen receptor containing a CD3? intracellular region with a Y/F mutation, includes an extracellular domain, a transmembrane domain, and an intracellular domain which are connected in sequence, where one end of the intracellular domain, which is connected to the transmembrane domain, is connected to the CD3? intracellular region with the Y/F mutation, and the CD3? intracellular region with the Y/F mutation refers to a Y/F mutant CD3? intracellular region in which both tyrosines are mutated to phenylalanines in the ITAM of the CD3? intracellular region. T cells modified with the chimeric antigen receptor have improved viability, decreased apoptosis level, and increased proliferation ability, and down-regulate the expression levels of cytokines IFN-? and TNF-?.